Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of Subcellular Localization on the Cytotoxicity of Targeted α-Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Photocontrolled trimethoprim PROTACs targeting the eDHFR protein tag.

Nature communications·2025
Same author

Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy.

Cancer discovery·2025
Same author

Practical considerations for clinical translation of PET imaging of adoptive cell therapies.

Npj imaging·2025
Same author

First-in-Human Biodistribution and Dosimetry of [<sup>11</sup>C]Trimethoprim.

Molecular imaging and biology·2025
Same author

Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery.

Small (Weinheim an der Bergstrasse, Germany)·2025

Related Experiment Video

Updated: Jul 8, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Tracking therapeutic T cells in vivo.

Angela Z Gong1, Mark A Sellmyer2

  • 1Department of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States; Department of Chemistry, University of Pennsylvania, Philadelphia, PA, United States.

Advances in Pharmacology (San Diego, Calif.)
|July 6, 2026
PubMed
Summary

Monitoring engineered cell therapies like CAR T-cells in vivo is crucial for patient response assessment and therapy improvement. Molecular imaging offers noninvasive, whole-body tracking to optimize these advanced treatments.

Keywords:
Direct labelingEngineered T cell therapiesMolecular imagingRadiolabelingReporter gene imaging

More Related Videos

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Related Experiment Videos

Last Updated: Jul 8, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
06:16

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

Area of Science:

  • Biotechnology
  • Immunotherapy
  • Medical Imaging

Background:

  • Engineered cell therapies, including chimeric antigen receptor (CAR) T-cell therapies, show significant promise for treating cancers and autoimmune diseases.
  • Seven CAR T-cell therapies are FDA-approved as of 2025, highlighting rapid advancements in the field.
  • A critical knowledge gap exists regarding the in vivo behavior of adoptively transferred cells.

Purpose of the Study:

  • To emphasize the importance of noninvasive methods for monitoring engineered T-cell dynamics in real time.
  • To highlight the role of imaging in assessing T-cell persistence, proliferation, functionality, and distribution.
  • To guide improvements in engineered cell therapy development and clinical treatment strategies.

Main Methods:

  • Discussing cell tracking and labeling strategies for engineered T-cell therapies.
  • Exploring molecular imaging techniques for noninvasive, whole-body cell monitoring.
  • Reviewing approaches compatible with therapeutic cell proliferation and persistence.

Main Results:

  • Molecular imaging enables noninvasive, long-term monitoring of adoptively transferred cells.
  • Imaging can assess key parameters like persistence, proliferation, functionality, and distribution.
  • These methods aid in real-time patient response assessment and therapy optimization.

Conclusions:

  • Noninvasive monitoring is essential for advancing engineered T-cell therapies.
  • Molecular imaging provides a powerful tool for tracking cell dynamics in vivo.
  • Optimized tracking strategies will improve therapeutic efficacy and clinical application.